| 1.07 -0.035 (-3.17%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.48  |
1-year : | 1.65 |
| Resists | First : | 1.27 |
Second : | 1.41 |
| Pivot price | 1.16 |
|||
| Supports | First : | 1.04 |
Second : | 0.87 |
| MAs | MA(5) : | 1.13 |
MA(20) : | 1.16 |
| MA(100) : | 1.38 |
MA(250) : | 2.04 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.5 |
D(3) : | 19.4 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 8.07 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BTAI ] has closed above bottom band by 15.7%. Bollinger Bands are 27.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.13 - 1.13 | 1.13 - 1.14 |
| Low: | 1.04 - 1.04 | 1.04 - 1.05 |
| Close: | 1.06 - 1.07 | 1.07 - 1.08 |
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.
Tue, 02 Jun 2026
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock - Yahoo Finance
Thu, 28 May 2026
BioXcel Therapeutics Presents New Data from SERENITY - GlobeNewswire
Fri, 22 May 2026
BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations - Stock Titan
Wed, 20 May 2026
BioXcel Therapeutics (BTAI) Rule 144: 6,845 shares from vested RSUs - Stock Titan
Fri, 15 May 2026
BioXcel at-home agitation drug gets Nov. 14, 2026 FDA action date - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 2.64e+007 (%) |
| Held by Institutions | 3.6 (%) |
| Shares Short | 3,950 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.011e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 962.6 % |
| Return on Equity (ttm) | -86.8 % |
| Qtrly Rev. Growth | 680000 % |
| Gross Profit (p.s.) | 72.9 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 796774 |
| Qtrly Earnings Growth | -4.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.09 |
| Dividend | 0 |
| Forward Dividend | 3.56e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|